Milestone Pharmaceuticals, Inc.
Developing fast-acting intranasal drugs to resolve cardiac rhythm disorders
Milestone Pharmaceutical develops novel small molecule therapeutics for transient cardiovascular conditions. The company’s lead product, etripamil (MSP-2017) is a potent, short-acting nasally-delivered calcium channel antagonist in phase 3 development for the episodic treatment of paroxysmal supraventricular tachycardia (PSVT).
- CEO Joseph Oliveto, MBA
- Industry Biotech